Alagebrium Chloride, formerly known as ALT711, was a drug candidate developed by Alteon, Inc. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs), thereby reversing one of the main mechanisms of aging. Through this effect Alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking. Alagebrium has proven effective in reducing systolic blood pressure and providing therapeutic benefit for patients with diastolic References: Toprak C, Sirmagul B, Yigitaslan S. Functional Effects of Alagebrium (ALT-711)-Isolated Rat Carotid Artery. Eurasian J Med. 2017 Oct;49(3):188-192. doi: 10.5152/eurasianjmed.2017.17046. PubMed PMID: 29123442; PubMed Central PMCID: PMC5665628.

纯度：≥98%

CAS：341028-37-3